Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 27;9:19864. doi: 10.1038/s41598-019-56462-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

AAV8-HLA-G1/5 Improves EAU clinical scores. Rats were treated by intravitreal (IVT) injections with scAAV8-HLAG1/5 (n = 6 rats, 12 eyes) or topically treated with dexamethasone (Dex) (n = 5 rats, 10eyes); no treatment experimental autoimmune uveitis (EAU) rat (n = 6 rats, 12 eyes) and healthy rats (untreated, no EAU induction) (n = 3 rats, 6 eyes) were used as controls. One week after IVT injections, EAU was induced by immunization with IRBP and ocular inflammation was examined by slit lamp biomicroscopy. (a) Bar graph of EAU clinical scores revealed that EAU clinical scores peaked at days 12 and 13 after uveitis induction. Mean clinical scores were significantly less in eyes treated with a single intravitreal dose of scAAV8-HLA-G1/5 or topical dexamethasone (applied topically every 6 hours) compared to untreated EAU eyes on each day from 12 through 14 post-induction (P = 0.03 to 0.001); Pairwise Wilcoxon tests). There were no significant differences in mean clinical scores between eyes treated with scAAV8 HLA-G1/5 or dexamethasone at any day. Healthy eyes had inflammatory scores of 0 for each day of the study. (b) Retinal images (top row) taken on day 9 did not reveal any gross retinal damage in any treatment group; topical corticosteroid treatment (A), HLAG1/5 (B), EAU no treatment (C), healthy or control rat (D). Representative images taken on day 12 after EAU induction, demonstrate dilated iris blood vessels, hypopyon, fibrin, posterior synechia and severe miosis in EAU eyes with no treatment (G), whereas normal eyes were observed in eyes treated with topical corticosteroids (E) and HLAG (F) treated rats; Healthy eye (H).